Use of a block polymer comprising a block of poly(3-(methacryloylamino)propyltrimethylammonium chloride) (PMAPTAC) for the neutralization of heparin

Patent metadata

Field	Value
Publication number	US-10052347-B2
Application number	US-201615579277-A
Country	US
Kind code	B2
Filing date	Jun 9, 2016
Priority date	Jun 10, 2015
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

The subject of the invention is use of block polymers with a block of poly(3-methacryloylpropyltrimethylammonium chloride) to direct neutralization of heparin, especially unfractionated heparin and low molecular weight heparins in the blood and other body fluids.

First claim

The invention claimed is:

1. A method for the direct neutralization of heparins in blood and body fluids comprising
applying a block copolymer containing poly(3-(methacryloylamino)propyltrimethylammonium chloride) (PMAPTAC), as one block of the block copolymer to the blood and body fluids containing heparins.

2. The method according to claim 1 , wherein the block copolymer is poly(ethylene glycol)-block-poly(3-(methacryloylamino)propyltrimethylammonium chloride) (PEG-PMAPTAC).

3. The method according to claim 1 , wherein the block copolymer is poly(2-(methacryloyloxy)ethyl phosphorylcholine-block-poly(3-(methacryloylamino)propyltrimethylammonium chloride) (PMPC-PMAPTAC).

4. The method according to claim 1 , wherein the block polymers comprising PMAPTAC are prepared by a method of controlled radical polymerization (CRP).

5. The method according to claim 2 , wherein the copolymer PEG-PMAPTAC is selected from the group consisting of PEG41-PMAPTAC53 and PEG41-PMAPTAC21.

6. The method according to claim 3 , wherein the copolymer PMPC-PMAPTAC is selected from the group consisting of PMPC20-PMAPTAC94 and PMPC100-PMAPTAC93.

7. The method according to claim 1 , wherein the heparins are selected from the group consisting of unfractionated heparin, and low-molecular-weight heparin.

8. The method according to claim 7 , wherein the block copolymer is PEG-PMAPTAC.

9. The method according to claim 8 , wherein the copolymer PEG-PMAPTAC is selected from the group consisting of PEG41-PMAPTAC53 and PEG41-PMAPTAC21.

10. The method according to claim 7 , wherein the block copolymer is PMPC-PMAPTAC.

11. The method according to claim 10 , wherein the copolymer PMPC-PMAPTAC is selected from the group consisting of PMPC20-PMAPTAC94 and PMPC100-PMAPTAC93.

12. The method according to claim 7 , wherein the block polymers comprising PMAPTAC are prepared by a method of controlled radical polymerization (CRP).

Assignees

• Univ Jagiellonski
• Univ Medyczny W Bialymstoku

Inventors

• Mogielnicki Andrzej
• Kalaska Bartlomiej
• Pawlak Dariusz
• Sokolowska Emilia
• Nowakowska Maria
• Szczubialka Krzysztof
• Kaminski Kamil

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• C08F2438/02

  Stable Free Radical Polymerisation [SFRP]; Nitroxide Mediated Polymerisation [NMP] for, e.g. using 2,2,6,6-tetramethylpiperidine-1-oxyl [TEMPO] · CPC title

• A61K31/785 Primary

  Polymers containing nitrogen · CPC title

• C08F2438/03

  Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX] · CPC title